Abstract
This study aimed to evaluate the effect of androgen deprivation therapy (ADT) on retinal vascular occlusion (RVO) development in patients with prostate cancer, using data from Taiwan’s National Health Insurance Research Database. A total of 1791, 1791, and 3582 patients were enrolled in the prostate cancer with ADT group, prostate cancer without ADT group, and the control group, respectively. The primary outcome was RVO occurrence, according to diagnostic codes. Cox proportional hazard regression was used to determine the adjusted hazard ratio (aHR) and 95% confidence interval (CI) of ADT and other covariates for RVO incidence. After a follow-up interval of up to 18 years, the patients with prostate cancer who received ADT showed significantly lower RVO incidence than the control group (aHR: 0.191, 95% CI: 0.059–0.621, p = 0.0059), after adjusting for multiple confounders. Hypertension was related to higher RVO incidence (aHR: 2.130, 95% CI: 1.127–4.027, p = 0.0199). Our overall results showed that using ADT for prostate cancer did not lead to a greater risk of RVO development. In fact, the patients with prostate cancer who received ADT had lower RVO incidence than those who did not receive ADT.
Highlights
Publisher’s Note: MDPI stays neutralProstate cancer is the second most common cancer among men, and represents the fifth leading cause of cancer death worldwide [1]
Regarding the type of Androgen deprivation therapy (ADT) used in the prostate cancer with ADT group, management was most commonly performed with antiandrogens, which were prescribed to >67% of individuals in the prostate cancer with ADT group, whereas estrogen was used with the least frequency (Table 1)
The patients with prostate cancer who received ADT showed significantly lower incidence of retinal vascular occlusion (RVO) than the patients in the control group, after adjusting for multiple potential confounders for RVO (Table 2)
Summary
Publisher’s Note: MDPI stays neutralProstate cancer is the second most common cancer among men, and represents the fifth leading cause of cancer death worldwide [1]. Androgen deprivation therapy (ADT) plays a critical role in the management of aggressive and advanced prostate cancer. Several randomized trials have indicated improved disease control and overall survival benefit with the addition of ADT to external beam radiotherapy [2,3]. Considering the overall survival improvement after ADT, in patients with advanced prostate cancer, there have been increasing concerns regarding treatment-related side effects that may significantly affect a patient’s quality of life, as well as cause mortality/morbidity. Reducing the amount of androgens may slow the tumor growth, with rapid and dramatic clinical benefits, it may impact other organs, causing numerous side effects, including hot flashes, sexual dysfunction, reduced musculoskeletal health, decreased insulin sensitivity, obesity, dyslipidemia, as well as potential harm to cardiovascular and with regard to jurisdictional claims in published maps and institutional affiliations
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
